职称：

教授

研究方向：

重大呼吸系统感染和肺损伤

研究工作：

呼吸道及神经系统新发突发传染病，新型冠状病毒（SARS-CoV-2）、中东呼吸综合征冠状病毒（MERS-CoV）、寨卡病毒（ZIKV），以及流感病毒等，从事病毒分离、动物模型建立、病毒感染引起的T细胞及体液免疫应答的作用机制及致病机制等，

科研项目：

1、国家重点研发计划“病原学与防疫技术体系研究” 重点专项，重要致病原及突变株的疫苗及药物有效性评价的动物模型体系建设和应用，冠状病毒及其突变株动物模型构建、疫苗及药物体内抗感染效果评价体系（项目2021YFC2301700），2021.12-2024.11，课题负责人。

2、国家重点研发计划“生物安全关键技术研究”重点专项，大流行风险病毒共性特征和通用防御关键技术（2022YFC2604100）, 2022.12-2025.11，子课题负责人。广东省自然科学基金杰出青年项目（2022B1515020059），新冠病毒灭活病毒疫苗及腺病毒载体疫苗序贯免疫保护作用及机制研究。2022-2026。2021。主持人。

3、国家自然科学基金“青年项目”（基金号81901623），病毒特异性记忆性CD4+ T细胞抗寨卡病毒感染的保护作用机制研究，2020-2022。主持。

代表性学术论文：

1、Jing Sun#, Zhen Zhuang#, Jian Zheng#, Kun Li#, Roy Lok-Yin Wong#, Donglan Liu#, Jicheng Huang#, Jiangping He#, Airu Zhu#, Jingxian Zhao#, Xiaobo Li#, Yin Xi#, … Paul B. McCray, Jr. *, Stanley Perlman*, Jincun Zhao*.Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020 Aug 6;182(3):734-743.e5. doi: 10.1016/j.cell.2020.06.010. (IF= 64.5)

2、Jing Sun#, Airu Zhu#, Heying Li#, Kui Zheng#, Zhen Zhuang#, Zhao Chen#, Yongxia Shi#, Zhaoyong Zhang#, Si-Bei Chen#, Xuesong Liu#, … Zifeng Yang*, Jicheng Huang*, Jincun Zhao*, Yi-Min Li*. Isolation of Infectious SARS-CoV-2 From Urine of a COVID-19 Patient. Emerg Microbes Infect. 2020 Dec;9(1):991-993.doi: 10.1080/22221751.2020.1760144.(IF= 13.2)

3、Fei Xiao #, Jing Sun #, Yonghao Xu #, Fang Li, Xiaofang Huang, Heying Li, Jingxian Zhao *, Jicheng Huang *, Jincun Zhao *. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. 2020. Emerg Infect Dis. 2020 Aug;26(8):1920-1922. doi: 10.3201/eid2608.200681 (IF= 11.8)

4、Lin, Yifan#; Sun, Jing#; Cao, Xuezhi#; Wang, Xiuye; Chen, Xi; Xu, Hairong; Zhao, Jincun; Fu, Yang-Xin; Peng, Hua, Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2., Cell Discov. 2022 May 10;8(1):43. doi: 10.1038/s41421-022-00411-4. (IF= 33.5)

5、Yan H#, Sun J#, Wang K, Wang H, Wu S, Bao L, He W, Wang D, Zhu A, Zhang T, Gao R, Dong B, Li J, Yang L, Zhong M, Lv Q, Qin F, Zhuang Z, Huang X, Yang X, Li Y, Che Y, Jiang J. 2021. Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm Sin B doi:10.1016/j.apsb.2021.02.024. (IF= 14.5)

6、Zhen Zhuang #, Xiaomin Lai #, Jing Sun #, Zhao Chen #, Zhaoyong Zhang #, Jun Dai #, Donglan Liu #, Yuming Li #, Fang Li #,…Jingxian Zhao*, Dongsheng Zhou*, Jincun Zhao*. Mapping and role of T cell response in SARS-CoV-2-infected mice. J Exp Med. 2021 Apr 5;218(4):e20202187. doi:10.1084/jem.20202187.(IF= 15.3)

7、Feng, Bo#; Chen, Zhilong#; Sun, Jing#; Xu, Tingting#; Wang, Qian; … Jinsong; Zhao, Jincun; Chen, Ling, A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape., Small Methods, 2022, e2200387. (IF=12.4)

8、Kang, Yin-Feng#; Sun, Cong#; Sun, Jing#; Xie, Chu; Zhuang, Zhen…; Zhao, Jin-Cun; Zeng, Mu-Sheng, Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants., Nature Communications, 2022, 13(1): 2674. (IF= 16.6)

9、Zhongfang Wang#, Xiaoyun Yang#, Yumin Zhou#, Jing Sun#, Xiaoqing Liu, Jing Zhang, Xinyue Mei, Jiaying Zhong, Jincun Zhao, Pixin Ran. COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury. Am J Respir Crit Care Med. 2020 Aug 15;202(4):606-610. (IF=24.7)

联系方式：

Email: sj-ji@163.com